Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles from Taipei
Based on 255 articles published since 2009
||||

These are the 255 published articles about Psoriasis that originated from Taipei during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11
1 Guideline Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. 2018

Yu, Kuang-Hui / Chen, Der-Yuan / Chen, Jiunn-Horng / Chen, Shih-Yang / Chen, Shyh-Ming / Cheng, Tien-Tsai / Hsieh, Song-Chou / Hsieh, Tsu-Yi / Hsu, Pai-Feng / Kuo, Chang-Fu / Kuo, Mei-Chuan / Lam, Hing-Chung / Lee, I-Te / Liang, Toong-Hua / Lin, Hsiao-Yi / Lin, Shih-Chang / Tsai, Wen-Pin / Tsay, Gregory J / Wei, James Cheng-Chung / Yang, Chung-Han / Tsai, Wen-Chan. ·Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan. · Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. · Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. · Ph.D. Program in Translational Medicine, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan. · Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. · School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. · Center of Gout, Country Hospital, Taipei, Taiwan. · Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan. · Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan. · Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Hsinchu, Taiwan. · Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. · Ph.D. Program of Business, Institute of Business, Feng-Chia University, Taichung, Taiwan. · Department of Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan. · Division of Nephrology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. · Faculty of Renal Care, Kaohsiung Medical University, Kaohsiung, Taiwan. · Division of Endocrinology and Metabolism, Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. · Rheumatology Section, Renai Branch, Taipei City Hospital, Taipei, Taiwan. · Division of Allergy, Immunology and Rheumatology, Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan. · Division of Rheumatology and Immunology, Cathay General Hospital, Taipei, Taiwan. · Department of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan. · Department of Immunology and Rheumatology, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan. · Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan. · Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. · Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. · Department of Internal Medicine, Landseed Hospital, Taoyuan, Taiwan. · Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. ·Int J Rheum Dis · Pubmed #29363262.

ABSTRACT: Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long-term urate-lowering treatment. Urate-lowering drugs should be used during the inter-critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate-lowering therapy should aim to maintain serum uric acid (sUA) level <6.0 mg/dL. For patients with tophi, the initial goal can be set at lowering sUA to <5.0 mg/dL to promote tophi dissolution. The goal of this consensus paper was to improve gout and hyperuricemia management at a more comprehensive level. The content of this consensus paper was developed based on local epidemiology and current clinical practice, as well as consensuses from two multidisciplinary meetings and recommendations from Taiwan Guideline for the Management of Gout and Hyperuricemia.

2 Editorial Pressing onward towards the goal: Engineering intelligent systems to improve clinical care. 2016

Wu, Chieh-Chen / Lu, Richard / Yang, Hsuan-Chia / Li, Yu-Chuan Jack. ·Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan. · Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan; International Center for Health Information Technology (ICHIT), Taipei Medical University, Taiwan. · Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan; Institute of Biomedical Informatics, National Yang Ming University, Taiwan. · Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan; International Center for Health Information Technology (ICHIT), Taipei Medical University, Taiwan; Chair, Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan. Electronic address: jack@tmu.edu.tw. ·Comput Methods Programs Biomed · Pubmed #26915273.

ABSTRACT: -- No abstract --

3 Review Neutrophils in Psoriasis. 2019

Chiang, Chih-Chao / Cheng, Wei-Jen / Korinek, Michal / Lin, Cheng-Yu / Hwang, Tsong-Long. ·Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. · Supervisor Board, Taoyuan Chinese Medicine Association, Taoyuan, Taiwan. · Puxin Fengze Chinese Medicine Clinic, Taoyuan, Taiwan. · School of Traditional Chinese Medicine, Chang Gung University, Taoyuan, Taiwan. · Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. · Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, Taiwan. · Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, and Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Taoyuan, Taiwan. · Department of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan. · Chinese Herbal Medicine Research Team, Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan. · Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. · Department of Chemical Engineering, Ming Chi University of Technology, New Taipei City, Taiwan. ·Front Immunol · Pubmed #31649677.

ABSTRACT: Neutrophils are the most abundant innate immune cells. The pathogenic roles of neutrophils are related to chronic inflammation and autoimmune diseases. Psoriasis is a chronic systemic inflammatory disease affecting ~2-3% of the world population. The abundant presence of neutrophils in the psoriatic skin lesions serves as a typical histopathologic hallmark of psoriasis. Recent reports indicated that oxidative stress, granular components, and neutrophil extracellular traps from psoriatic neutrophils are related to the initial and maintenance phases of psoriasis. This review provides an overview on the recent (up to 2019) advances in understanding the role of neutrophils in the pathophysiology of psoriasis, including the effects of respiratory burst, degranulation, and neutrophil extracellular trap formation on psoriatic immunity and the clinical relationships.

4 Review A review of antibiotics and psoriasis: induction, exacerbation, and amelioration. 2019

Tsai, Ya-Chu / Tsai, Tsen-Fang. ·Department of Dermatology, Far Eastern Memorial Hospital , New Taipei , Taiwan. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine , Taipei , Taiwan. ·Expert Rev Clin Pharmacol · Pubmed #31498683.

ABSTRACT:

5 Review Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis. 2019

Huang, Tse-Hung / Lin, Chwan-Fwu / Alalaiwe, Ahmed / Yang, Shih-Chun / Fang, Jia-You. ·Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung 204, Taiwan. huangtsehung@gmail.com. · School of Traditional Chinese Medicine, Chang Gung University, Kweishan, Taoyuan 333, Taiwan. huangtsehung@gmail.com. · Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Kweishan, Taoyuan 333, Taiwan. huangtsehung@gmail.com. · School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei 112, Taiwan. huangtsehung@gmail.com. · Department of Cosmetic Science, Chang Gung University of Science and Technology, Kweishan, Taoyuan 333, Taiwan. cflin@mail.cgust.edu.tw. · Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan 333, Taiwan. cflin@mail.cgust.edu.tw. · Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan 333, Taiwan. cflin@mail.cgust.edu.tw. · Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj 11942, Saudi Arabia. alalaiwe@gmail.com. · Department of Cosmetic Science, Providence University, Taichung 433, Taiwan. yangsc@pu.edu.tw. · Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan 333, Taiwan. fajy@mail.cgu.edu.tw. · Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan 333, Taiwan. fajy@mail.cgu.edu.tw. · Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Kweishan, Taoyuan 333, Taiwan. fajy@mail.cgu.edu.tw. · Chinese Herbal Medicine Research Team, Healthy Aging Research Center, Chang Gung University, Kweishan, Taoyuan 333, Taiwan. fajy@mail.cgu.edu.tw. ·Int J Mol Sci · Pubmed #31137673.

ABSTRACT: Natural products or herbs can be used as an effective therapy for treating psoriasis, an autoimmune skin disease that involves keratinocyte overproliferation. It has been demonstrated that phytomedicine, which is used for psoriasis patients, provides some advantages, including natural sources, a lower risk of adverse effects, and the avoidance of dissatisfaction with conventional therapy. The herbal products' structural diversity and multiple mechanisms of action have enabled the synergistic activity to mitigate psoriasis. In recent years, the concept of using natural products as antiproliferative agents in psoriasis treatment has attracted increasing attention in basic and clinical investigations. This review highlights the development of an apoptotic or antiproliferatic strategy for natural-product management in the treatment of psoriasis. We systematically introduce the concepts and molecular mechanisms of keratinocyte-proliferation inhibition by crude extracts or natural compounds that were isolated from natural resources, especially plants. Most of these studies focus on evaluation through an in vitro keratinocyte model and an in vivo psoriasis-like animal model. Topical delivery is the major route for the in vivo or clinical administration of these natural products. The potential use of antiproliferative phytomedicine on hyperproliferative keratinocytes suggests a way forward for generating advances in the field of psoriasis therapy.

6 Review Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. 2018

Ho, Po-Han / Tsai, Tsen-Fang. ·Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. ·J Dermatol · Pubmed #30230584.

ABSTRACT: Juvenile generalized pustular psoriasis (GPP) is rare and often resistant to conventional systemic therapy such as methotrexate, retinoic acid and cyclosporin A. GPP can be induced by deficiency of interleukin (IL)-36 receptor antagonist (DITRA). No standardized guidelines are available for juvenile GPP or DITRA, and a uniformly safe and effective biologic agent has not been identified. However, multiple biologics approved for use in plaque-type psoriasis have also been used in GPP. Herein, we report a case of a 6-year-old Taiwanese boy with GPP and homozygous mutation at c.115+6T>C within the IL-36 receptor antagonist (IL36RN) gene, who was treated successfully with secukinumab after failure of prior methotrexate, acitretin, cyclosporin A, etanercept and adalimumab. Similar to two previously reported non-adult cases of GPP successfully treated with secukinumab, our case also demonstrated a history of repeated treatment failures with several conventional oral systemic agents and biologics. Different from these two cases, however, ours is the first of juvenile GPP successfully treated with secukinumab monotherapy, without using other systemic agent concurrently during the use of secukinumab.

7 Review Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. 2018

Hawkes, Jason E / Yan, Bernice Y / Chan, Tom C / Krueger, James G. ·Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065; and. · Department of Dermatology, National Taiwan University Hospital and College of Medicine, Taipei 10002, Taiwan. · Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065; and kruegej@rockefeller.edu. ·J Immunol · Pubmed #30181299.

ABSTRACT: Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also associated with multiple comorbid conditions, such as joint destruction, cardiovascular disease, stroke, hypertension, metabolic syndrome, and chronic kidney disease. The discovery of IL-17-producing T cells in a mouse model of autoimmunity transformed our understanding of inflammation driven by T lymphocytes and associations with human inflammatory diseases, such as psoriasis. Under the regulation of IL-23, T cells that produce high levels of IL-17 create a self-amplifying, feed-forward inflammatory response in keratinocytes that drives the development of thickened skin lesions infiltrated with a mixture of inflammatory cell populations. Recently, the Food and Drug Administration approved multiple highly effective psoriasis therapies that disrupt IL-17 (secukinumab, ixekizumab, and brodalumab) and IL-23 (guselkumab and tildrakizumab) signaling in the skin, thus leading to a major paradigm shift in the way that psoriatic disease is managed.

8 Review Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. 2018

Chyuan, I-Tsu / Chen, Ji-Yih. ·Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan. · Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. · Department of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. ·Mediators Inflamm · Pubmed #29670461.

ABSTRACT: Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Further evidence from human and animal studies have defined that IL-17 and IL-17-producing cells contribute to tissue inflammation, autoimmunity, and host defense, leading to the following pathologic events associated with SpA. Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. In this review article, we have discussed the contributing role of IL-17 and different IL-17-producing cells in the pathogenesis of SpA and provided an outline of therapeutic application of the IL-17 blockade in the treatment of SpA. Other targeted cytokines associated with IL-17 axis in SpA will also be included.

9 Review Murine models of psoriasis and their usefulness for drug discovery. 2018

Chuang, Shih-Yi / Lin, Chih-Hung / Sung, Calvin T / Fang, Jia-You. ·a Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine , Chang Gung University of Science and Technology , Taoyuan , Taiwan. · b Center for General Education , Chang Gung University of Science and Technology , Taoyuan , Taiwan. · c School of Medicine , University of California , Riverside , USA. · d Pharmaceutics Laboratory, Graduate Institute of Natural Products , Chang Gung University , Taoyuan , Taiwan. · e Chinese Herbal Medicine Research Team, Healthy Aging Research Center , Chang Gung University , Taoyuan , Taiwan. · f Department of Anesthesiology , Chang Gung Memorial Hospital , Taoyuan , Taiwan. ·Expert Opin Drug Discov · Pubmed #29663834.

ABSTRACT: INTRODUCTION: Psoriasis is an autoimmune skin disease characterized by red plaques with silver or white multilayered scales with a thickened acanthotic epidermis. Using mouse models of cutaneous inflammation, IL-23/Th17 was identified to have a potential key role in psoriasis. New treatments to slow this inflammatory skin disorder are urgently needed. To aid their discovery, a psoriasis animal model mimicking human psoriasis is urgently needed for their early preclinical evaluation. Areas covered: The authors review animal models of psoriasis and analyze the features and molecular mechanisms involved in these mouse models. The application of various mouse models of psoriasis for drug discovery and development has also been reviewed and the possible molecular targets in psoriasis for future anti-psoriatic drug design is discussed. Expert opinion: So far, it has been difficult to create an animal model that exactly simulates a human disease or condition. The xenotransplantation model is regarded as the closest to incorporating the complete genetic, phenotypic, and immunopathogenic processes of psoriasis. However, the imiquimod (IMQ)-induced model is the most prevalent among psoriatic mouse models due to its ease of use, convenience, and low cost. Further efforts to develop psoriasis-like skin models in mice are needed for the study and treatment of this complex disease.

10 Review The expression and function of galectins in skin physiology and pathology. 2018

Wu, Nan-Lin / Liu, Fu-Tong. ·Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. · Department of Dermatology, MacKay Memorial Hospital, Taipei, Taiwan. · Mackay Junior College of Medicine, Nursing, and Management, New Taipei City, Taiwan. · Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. · Department of Dermatology, University of California Davis, Sacramento, CA, USA. ·Exp Dermatol · Pubmed #29427464.

ABSTRACT: The galectin family comprises β-galactoside-binding proteins widely expressed in many organisms. There are at least 16 family members, which can be classified into three groups based on their carbohydrate-recognition domains. Pleiotropic functions of different galectins in physiological and pathological processes through extracellular or intracellular actions have been revealed. In the skin, galectins are expressed in a variety of cells, including keratinocytes, melanocytes, fibroblasts, dendritic cells, lymphocytes, macrophages and endothelial cells. Expression of specific galectins is reported to affect cell status, such as activation or death, and regulate the interaction between different cell types or between cells and the extracellular matrix. In vitro cellular studies, in vivo animal studies and studies of human clinical material have revealed the pathophysiologic roles of galectins in the skin. The pathogenesis of diverse non-malignant skin disorders, such as atopic dermatitis, psoriasis, contact dermatitis and wound healing, as well as skin cancers, such as melanoma, squamous cell carcinoma, basal cell carcinoma and cutaneous haematologic malignancy can be regulated by different galectins. Revelation of biological roles of galectins in skin may pave the way to future development of galectin-based therapeutic strategies for skin diseases.

11 Review Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. 2018

Kuo, C-M / Tung, T-H / Wang, S-H / Chi, C-C. ·School of Medicine, Tzu Chi University, Hualien, Taiwan. · Department of Medical Research and Education, Cheng Hsin General Hospital, Taipei, Taiwan. · Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan. · Graduate Institute of Applied Science and Engineering, College of Science and Engineering, Fu Jen Catholic University, New Taipei, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Chiayi, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. ·J Eur Acad Dermatol Venereol · Pubmed #29136293.

ABSTRACT: The effects of tofacitinib in treating moderate-to-severe plaque psoriasis were unclear. We aimed to assess the effects of tofacitinib in treating moderate-to-severe plaque psoriasis. We searched PubMed, Cochrane Central Register of Controlled Trials and EMBASE for relevant randomized controlled trials (RCTs) and conducted a systematic review and meta-analysis. Four RCTs with 2724 participants were included. Compared to placebo, tofacitinib significantly improved psoriasis {≥75% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: risk difference (RD) 0.32 [95% confidence interval (CI) 0.28-0.35], 10 mg BID: RD 0.51 (95% CI 0.43-0.58); ≥90% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: RD 0.19 (95% CI 0.17-0.22), 10 mg BID: RD 0.36 (95% CI 0.31-0.42); Physician's Global Assessment 0/1: 5 mg BID: RD 0.31 (95% CI 0.27-0.35), 10 mg BID: RD 0.48 (95% CI 0.44-0.53)} and participants' life quality [Dermatology Life Quality Index 0/1: 5 mg BID: RD 0.24 (95% CI 0.20-0.2), 10 mg BID: RD 0.36 (95% CI 0.33-0.40)]. Tofacitinib was associated with an increase in minor adverse events [upper respiratory tract infection: 5 mg BID: RD 0.02 (95% CI 0.00-0.03), 10 mg BID: RD 0.02 (95% CI 0.00-0.04); hypercholesterolaemia: 5 mg BID: RD 0.02 (95% CI 0.01-0.04), 10 mg BID: RD 0.02 (95% CI 0.01-0.04)]. In conclusion, tofacitinib may be a treatment option for moderate-to-severe plaque psoriasis that is unresponsive to other therapies and patients who are intolerable to other therapies or prefer oral medications.

12 Review HLA-Cw6 and psoriasis. 2018

Chen, L / Tsai, T-F. ·Lake Erie College of Osteopathic Medicine, Bradenton, PA, U.S.A. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan. ·Br J Dermatol · Pubmed #29072309.

ABSTRACT: Psoriasis is a multifactorial disease with a strong genetic background. HLA-Cw6 is one of the most strongly associated psoriasis susceptibility alleles. It is repeatedly observed to affect disease course, phenotypic features, severity, comorbidities and treatment outcomes. To the best of our knowledge, the roles of HLA-Cw6 in psoriasis have not yet been thoroughly reviewed. The worldwide frequency of the HLA-Cw6 allele varies greatly, with it being generally higher in white people than in Asians. The allele is associated with type I early-onset psoriasis. Stress, obesity and streptococcal pharyngitis are commonly observed in HLA-Cw6-positive patients. Phenotypically, HLA-Cw6 has been found to be associated with guttate psoriasis. In addition, patients carrying the allele are more likely to have arm, leg and trunk involvement, and the Koebner phenomenon. Patients with psoriatic arthritis with HLA-Cw6 more often have early onset and tend to show cutaneous symptoms before musculoskeletal symptoms. HLA-Cw6-positive patients have been shown in several studies to be more responsive to methotrexate and ustekinumab. However, this difference in ustekinumab efficacy was only moderate in a post-hoc analysis of a pivotal phase III study. HLA-Cw6 positivity also tends to be less frequent in high-need patients who fail conventional therapy. Small studies have also investigated the role of HLA-Cw6 in remission of psoriasis during pregnancy, and with the comorbidities of photosensitivity and atherosclerosis. Given the diverse nature of psoriasis pathogenesis, as well as the difference of HLA-Cw6 positivity in different ethnic groups, more studies are needed to confirm the role of HLA-Cw6 in psoriasis.

13 Review Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. 2017

Tsai, Ya-Chu / Tsai, Tsen-Fang. ·Far Eastern Memorial Hospital, New Taipei City, Taiwan. · National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100, Taiwan. ·Ther Adv Musculoskelet Dis · Pubmed #29344110.

ABSTRACT: Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38).

14 Review Tofacitinib in psoriatic arthritis. 2017

Wang, Ting-Shun / Tsai, Tsen-Fang. ·Division of Dermatology, Chung Shan Medical University Hospital, Taichung, Taiwan. · Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan. ·Immunotherapy · Pubmed #28967798.

ABSTRACT: Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents. Tofacitinib is a Janus family of kinases inhibitor approved for treating rheumatoid arthritis in many countries and psoriasis in Russia. We reviewed the evidences of tofacitinib in psoriatic arthritis treatment. The efficacy and safety profiles result from Phase III clinical trials (OPAL BROADEN and OPAL BEYOND) and one open-label extension study (OPAL BALANCE). Both tofacitinib 5 or 10 mg twice a day were superior to placebo for American College of Rheumatology 20% improvement criteria response at 3 months and showed significant improvement of skin, enthesitis and dactylitis. Tofacitinib is a promising treatment option for psoriatic arthritis.

15 Review Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation. 2017

Lai, Chao-Yang / Su, Yu-Wen / Lin, Kuo-I / Hsu, Li-Chung / Chuang, Tsung-Hsien. ·Immunology Research Center, National Health Research Institutes, Miaoli 35053, Taiwan. · Genomics Research Center, Academia Sinica, Taipei 115, Taiwan. · Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei 10002, Taiwan. · Program in Environmental and Occupational Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. ·J Immunol Res · Pubmed #28894754.

ABSTRACT: Psoriasis is a chronic inflammatory autoimmune disease that can be initiated by excessive activation of endosomal toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9. Therefore, inhibitors of endosomal TLR activation are being investigated for their ability to treat this disease. The currently approved biological drugs adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, and secukizumab are antibodies against effector cytokines that participate in the initiation and development of psoriasis. Several immune modulatory oligonucleotides and small molecular weight compounds, including IMO-3100, IMO-8400, and CPG-52364, that block the interaction between endosomal TLRs and their ligands are under clinical investigation for their effectiveness in the treatment of psoriasis. In addition, several chemical compounds, including AS-2444697, PF-05387252, PF-05388169, PF-06650833, ML120B, and PHA-408, can inhibit TLR signaling. Although these compounds have demonstrated anti-inflammatory activity in animal models, their therapeutic potential for the treatment of psoriasis has not yet been tested. Recent studies demonstrated that natural compounds derived from plants, fungi, and bacteria, including mustard seed,

16 Review Acupuncture-Related Techniques for Psoriasis: A Systematic Review with Pairwise and Network Meta-Analyses of Randomized Controlled Trials. 2017

Yeh, Mei-Ling / Ko, Shu-Hua / Wang, Mei-Hua / Chi, Ching-Chi / Chung, Yu-Chu. ·1 Graduate Institute of Integration of Traditional Chinese Medicine with Western Nursing, National Taipei University of Nursing and Health Sciences , Taipei, Taiwan, Republic of China . · 2 Chong-Ren Hospital , Miaoli, Taiwan, Republic of China . · 3 School of Nursing, National Taipei University of Nursing and Health Sciences , Taipei, Taiwan, Republic of China . · 4 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Chang Gung University College of Medicine , Taoyuan, Taiwan, Republic of China . · 5 Department of Nursing, Yuanpei University of Medical Technology , Hsinchu, Taiwan, Republic of China . ·J Altern Complement Med · Pubmed #28628749.

ABSTRACT: OBJECTIVE: There has be a large body of evidence on the pharmacological treatments for psoriasis, but whether nonpharmacological interventions are effective in managing psoriasis remains largely unclear. This systematic review conducted pairwise and network meta-analyses to determine the effects of acupuncture-related techniques on acupoint stimulation for the treatment of psoriasis and to determine the order of effectiveness of these remedies. METHODS: This study searched the following databases from inception to March 15, 2016: Medline, PubMed, Cochrane Central Register of Controlled Trials, EBSCO (including Academic Search Premier, American Doctoral Dissertations, and CINAHL), Airiti Library, and China National Knowledge Infrastructure. Randomized controlled trials (RCTs) on the effects of acupuncture-related techniques on acupoint stimulation as intervention for psoriasis were independently reviewed by two researchers. RESULTS: A total of 13 RCTs with 1,060 participants were included. The methodological quality of included studies was not rigorous. Acupoint stimulation, compared with nonacupoint stimulation, had a significant treatment for psoriasis. However, the most common adverse events were thirst and dry mouth. Subgroup analysis was further done to confirm that the short-term treatment effect was superior to that of the long-term effect in treating psoriasis. Network meta-analysis identified acupressure or acupoint catgut embedding, compared with medication, and had a significant effect for improving psoriasis. It was noted that acupressure was the most effective treatment. CONCLUSIONS: Acupuncture-related techniques could be considered as an alternative or adjuvant therapy for psoriasis in short term, especially of acupressure and acupoint catgut embedding. This study recommends further well-designed, methodologically rigorous, and more head-to-head randomized trials to explore the effects of acupuncture-related techniques for treating psoriasis.

17 Review Image Gallery: Resolution of lichen striatus in a patient with coexisting chronic plaque psoriasis and vitiligo during secukinumab treatment. 2017

Yang, C-W / Tsai, T-F. ·Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. ·Br J Dermatol · Pubmed #28504405.

ABSTRACT: -- No abstract --

18 Review Risk of Suicidality in People with Psoriasis: A Systematic Review and Meta-Analysis of Cohort Studies. 2017

Chi, Ching-Chi / Chen, Ting-Hao / Wang, Shu-Hui / Tung, Tao-Hsin. ·Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Chiayi, Chiayi, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. · Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan. · Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan. · Graduate Institute of Applied Science and Engineering, College of Science and Engineering, Fu Jen Catholic University, New Taipei, Taiwan. · Department of Medical Research and Education, Cheng Hsin General Hospital, 45, Cheng Hsin St, Pai-Tou, Taipei, 11220, Taiwan. ch2876@chgh.org.tw. · Department of Public Health, Fu Jen Catholic University, New Taipei, Taiwan. ch2876@chgh.org.tw. ·Am J Clin Dermatol · Pubmed #28409490.

ABSTRACT: BACKGROUND: Psoriasis has been associated with psychiatric disorders such as depression and anxiety, but its relationship with suicidality (including suicide, suicide attempt, and suicidal ideation) is unclear. OBJECTIVE: Our objective was to assess the risk of suicide, suicide attempt, suicidal ideation, and suicidality in people with psoriasis. METHODS: We conducted a systematic review and meta-analysis of cohort studies examining the risk of suicide, suicide attempt, suicidal ideation, and suicidality in people with psoriasis. We searched the Cochrane Library, PubMed, and EMBASE from inception to 24 March 2017. Two authors independently selected studies, assessed the quality of included studies, and extracted data. Any disagreement was resolved by discussion with a third author. RESULTS: Five population-based cohort studies were included and considered to be of high quality. We found no increase in the risk of suicide (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.87-1.46), suicide attempt (RR 1.25; 95% CI 0.89-1.75), or suicidality (RR 1.26; 95% CI 0.97-1.64) among people with psoriasis. In the stratified analysis, we also found no increase in suicide, suicide attempt, and suicidality among people with either severe or mild psoriasis. CONCLUSIONS: The available limited, very low-quality evidence does not support an association between psoriasis and suicidal thought and behavior. Further studies that provide data for different age and sex groups are needed to clarify whether a subgroup of patients with psoriasis has an elevated risk of suicidality.

19 Review Risks for Staphylococcus aureus colonization in patients with psoriasis: a systematic review and meta-analysis. 2017

Ng, C Y / Huang, Y H / Chu, C F / Wu, T C / Liu, S H. ·Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan. · College of Medicine, Chang Gung University, Gueishan District, Taoyuan City, Taiwan. · Graduate Institute of Clinical Medical Sciences, Chang Gung University, Gueishan District, Taoyuan City, Taiwan. · Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan. ·Br J Dermatol · Pubmed #28160277.

ABSTRACT: Evidence on whether patients with psoriasis have a higher risk for staphylococcal colonization than healthy controls remains controversial. To synthesize the current literature, we performed a systematic review on the prevalence and relative risk (RR) of Staphylococcus aureus colonization in patients with psoriasis. We modified the QUADAS-2 instrument to assess the reporting quality of individual studies and applied random-effects models in meta-analysis. Overall we identified 21 eligible studies, of which 15 enrolled one or more comparison groups. The pooled prevalence of staphylococcal colonization in patients with psoriasis was 35·3% [95% confidence interval (CI) 25·0-45·6] on lesional skin and 39·2% (95% CI 33·7-44·8) in the nares. Patients with psoriasis were 4·5 times more likely to be colonized by S. aureus than healthy controls were on the skin (RR 5·54, 95% CI 3·21-9·57) and 60% more in the nares (RR 1·60, 95% CI 1·11-2·32). Cutaneous and nasal colonization by meticillin-resistant S. aureus also appeared higher in patients with psoriasis (pooled prevalence 8·6%) than in healthy controls (2·6%), yet the difference was not statistically significant (P = 0·74). In contrast, despite of a similar risk for nasal staphylococcal colonization (RR 0·67, 95% CI 0·38-1·18), patients with psoriasis were less likely to carry S. aureus on lesional skin than atopic patients (RR 0·64, 95% CI 0·40-1·02). In summarizing the current literature, we found that patients with psoriasis were at an increased risk for staphylococcal colonization compared with healthy individuals. Prospective studies on how bacterial loads correlate with disease activity can guide the clinical management of bacterial colonization while preventing the emergence of drug-resistant strains.

20 Review Managing Scalp Psoriasis: An Evidence-Based Review. 2017

Wang, Ting-Shun / Tsai, Tsen-Fang. ·Department of Dermatology, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, #7, Chung-Shan South Road, Taipei, Taiwan. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, #7, Chung-Shan South Road, Taipei, Taiwan. tftsai@yahoo.com. ·Am J Clin Dermatol · Pubmed #27650520.

ABSTRACT: BACKGROUND: Scalp psoriasis is commonly the initial presentation of psoriasis, and almost 80 % of patients with psoriasis will eventually experience it. OBJECTIVE: Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely. METHODS: Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature. RESULTS: To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in scalp psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol-betamethasone dipropionate is well tolerated and more effective than either of its individual components. Localized phototherapy is better than generalized phototherapy on hair-bearing areas. Methotrexate, cyclosporine, fumaric acid esters, and acitretin are well-recognized agents in the treatment of psoriasis, but we found no published RCTs evaluating these agents specifically in scalp psoriasis. Biologics and new small-molecule agents show excellent effects on scalp psoriasis, but the high cost of these treatments mean they may be limited to use in extensive scalp psoriasis. CONCLUSIONS: More controlled studies are needed for an evidence-based approach to scalp psoriasis.

21 Review A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. 2016

Tsai, Ya C / Tsai, Tsen F. ·Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan - tftsai@yahoo.com. ·G Ital Dermatol Venereol · Pubmed #26889727.

ABSTRACT: INTRODUCTION: Biologics are increasingly used in the treatment of moderate to severe psoriasis. However, most of the pivotal studies were performed mainly in western countries. The purpose of this review article was to compare the differences of clinical trial results between Asian and Western subjects of psoriasis regarding baseline demographics, efficacy, dermatology life quality index, safety and antidrug antibodies. EVIDENCE ACQUISITION: In this review article, we searched the PubMed/Medline, ClinicalTrials.gov, and posters from main dermatologic meetings. EVIDENCE SYNTHESIS: Only randomized controlled trial results or trial results for registration purposes of etanercept, adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, guselkumab, tofacitinib, and apremilast are included. CONCLUSIONS: Asian subjects were generally 15-20 Kgs lighter, with fewer psoriatic arthritis, shorter disease duration since diagnosis, and higher baseline severity compared to western subjects. Better efficacy had been found in some studies such as secukinumab, brodalumab, ixekizumab, and tofacitinib in Japanese groups. The safety in Asian trials was generally compatible with the pivotal studies, except for the occurrence of active tuberculosis in the infliximab trial in China. Additional indications of pustular and erythrodermic psoriasis are approved in Japan for some of the agents based on phase II/III studies.

22 Review Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. 2014

Wang, Shu-Hui / Chi, Ching-Chi / Hu, Sindy. ·Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan; Department of Healthcare Administration, Oriental Institute of Technology, New Taipei, Taiwan; Department of Cosmetic Science, Chang Gung University of Science and Technology, Taoyuan, Taiwan. ·Int J Dermatol · Pubmed #24738910.

ABSTRACT: BACKGROUND: Biologic therapies are more effective than conventional therapies in the treatment of psoriasis, but they are also more costly. OBJECTIVES: The aim of this study was to compare the cost-efficacy of etanercept, adalimumab, and ustekinumab therapies in the treatment of moderate to severe psoriasis in a Taiwanese setting. METHODS: We conducted a meta-analysis of randomized, placebo-controlled trials to calculate the incremental efficacy of etanercept, adalimumab, and ustekinumab, respectively, in affecting a reduction of ≥75% in score on the Psoriasis Area and Severity Index (PASI 75). The base, best case, and worst case incremental cost-effectiveness ratios (ICERs) for one subject to achieve PASI 75 were calculated for the purposes of economic analysis. RESULTS: One-year ICERs per PASI 75 responder were US$ 39,709 (best scenario US$ 36,400; worst scenario US$ 43,680), US$ 23,711 (best scenario US$ 22,633; worst scenario US$ 25,319), and US$ 26,329 (best scenario US$ 24,780; worst scenario US$ 27,623) for etanercept, adalimumab, and ustekinumab, respectively. Two year ICERs per PASI 75 responder were US$ 71,973 (best scenario US$ 65,975; worst scenario US$ 79,170), US$ 62,665 (best scenario US$ 59,817; worst scenario US$ 66,914), and US$ 52,657 (best scenario US$ 49,560; worst scenario US$ 55,427) for etanercept, adalimumab, and ustekinumab, respectively. CONCLUSIONS: In a Taiwanese setting, adalimumab and ustekinumab had lower 1-year costs per PASI 75 responder than etanercept, and ustekinumab had the lowest 2-year cost per PASI 75 responder.

23 Review Intralesional therapy for psoriasis. 2013

Wang, Ting-Shun / Tsai, Tsen-Fang. ·Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China. ·J Dermatolog Treat · Pubmed #22390539.

ABSTRACT: Localized resistant plaques of psoriasis often remain despite highly effective anti-psoriasis treatment. Intralesional therapy is often used to treat various malignant, infectious or inflammatory cutaneous diseases, including psoriasis. Despite the presence of many review articles on the treatment of psoriasis, no articles exist which review the use of intralesional therapy for psoriasis. In this article, we review the published literatures of intralesional therapy for psoriasis. Corticosteroids, methotrexate, cyclosporin, biologics, botulinum toxin type-A, 15-hydroxyeicosatetraenoic acid, and chemotherapy agents such as 5-fluorouracil are discussed. Also, agents which may be used intralesionally and have the potential to treat psoriasis will also be reviewed such as bleomycin, vincristine or vinblastine, mitomycin-C, aminophylline, 5-aminolevulinic acid, rituximab, bevacizumab and pentoxifylline are included.

24 Review Psoriasis and cardiovascular comorbidities with emphasis in Asia. 2012

Chu, T W / Tsai, T F. ·Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan. tftsai@yahoo.com ·G Ital Dermatol Venereol · Pubmed #22481582.

ABSTRACT: Psoriasis is traditionally considered a skin-specific disease with the exception of coexisting psoriatic arthritis. However, growing evidence suggests a link between psoriasis and other comorbidities. Cardiovascular comorbidity, in particular, is the focus of considerable research, due in part to the associated mortality and possible intervention. A common mechanism that may explain both psoriasis and atherosclerosis pathogenesis is of great interest and utility. The increase of Th1 and Th17 leading to chronic inflammation is thought to be a patho-denominator for both diseases. In addition, progressive adiposity and resultant metabolic syndrome are but the beginning steps in the "psoriatic march". In this article, we review the recent publications on cardiovascular risks in patients with psoriasis. We also examine the effects of psoriasis treatment, including the new biologics, on cardiovascular comorbidities. Although there is generally a lack of Asian research on this issue, we present the most recent pertinent findings from Taiwan.

25 Review Allopurinol in dermatology. 2010

Tsai, Tsen-Fang / Yeh, Ting-Yu. ·Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan. tftsai@yahoo.com ·Am J Clin Dermatol · Pubmed #20509717.

ABSTRACT: Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has spurred renewed interest in its application in other clinical specialties. In dermatology, allopurinol is best known for its severe cutaneous adverse reactions. Recent genomic studies conducted in Taiwan have discovered useful HLA markers for determining the susceptibility of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with allopurinol. Allopurinol has also been used in a number of dermatologic disorders including acquired reactive perforating collagenosis, sarcoidosis, psoriasis and granulomas caused by methacrylate microspheres, silicon and tattoos. Allopurinol may express its therapeutic effects via its antioxidation or anti-inflammatory properties, or its ability to improve vascular function.

Next